MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival

Biology Direct

Volumn 6, Issue , 2011, Pages

  Chi, Jianxiang ^a,b   Ballabio, Erica ^a   Chen, Xiao He ^a   Kušec, Rajko ^c   Taylor, Steve ^d   Hay, Deborah ^e   Tramonti, Daniela ^a   Saunders, Nigel J ^f   Littlewood, Timothy ^e   Pezzella, Francesco ^a   Boultwood, Jacqueline ^a   Wainscoat, James S ^a   Hatton, Christian S R ^e   Lawrie, Charles H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b The Center for the Study of Haematological Malignancies   (Cyprus)

^c University of Zagreb School of Medicine   (Croatia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADULT; AGED; ARTICLE; CLASSIFICATION; CLUSTER ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOLOGY; PLASMACYTOMA; PROGNOSIS; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSLOCATION, GENETIC; UP-REGULATION;

EID: 79955958422     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-6-23     Document Type: Article

References (53)

1. Ries L, Eisner M, Kosary C. SEER Cancer Statistics Review, 1975-2001 2004, Bethesda: National Cancer Institute.
2. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010, 28:2259-2266. 10.1200/JCO.2009.26.0638, 20368561.
3. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801. 10.1056/NEJMoa050995, 16251535.
4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
5. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007, 121:1156-1161. 10.1002/ijc.22800, 17487835.
6. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675. 10.1111/j.1365-2141.2008.07077.x, 18318758.
7. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009, 13:1248-1260. 10.1111/j.1582-4934.2008.00628.x, 19413891.
8. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
9. Lawrie CH. microRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?. J Cell Mol Med 2008, 12:1432-1444. 10.1111/j.1582-4934.2008.00399.x, 18624758.
10. Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, Tosi I, Vermeer MH, Tramonti D, Saunders NJ, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010, 116:1105-1113. 10.1182/blood-2009-12-256719, 20448109.
11. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 107:7904-7909.
12. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008, 105:12885-12890. 10.1073/pnas.0806202105, 2529070, 18728182.
13. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002, 21:4663-4670. 10.1093/emboj/cdf476, 126204, 12198168.
14. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369. 3, 10.1056/NEJMoa054494, 16571879.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028. 10.1182/blood-2005-11-013458, 1895543, 16728703.
16. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221. 10.1038/leu.2009.174, 2964268, 19798094.
17. Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RK, Strike P, Gunasekera JL, Jones A, Harrison CJ, et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 2005, 19:1634-1642. 10.1038/sj.leu.2403857, 15990862.
18. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2005, 346-352.
19. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637. 10.1038/leu.2009.274, 20054351.
20. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114:e20-26. 10.1182/blood-2009-08-237495, 19846888.
21. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420. 10.1200/JCO.2005.04.242, 15809451.
22. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 2001, 28:29-37. 10.1038/sj.bmt.1703093, 11498741.
23. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33. 10.4065/78.1.21, 12528874.
24. Shustik C, Bergsagel DE, Pruzanski W. Kappa and lambda light chain disease: survival rates and clinical manifestations. Blood 1976, 48:41-51.
25. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008, 10:202-210. 10.1038/ncb1681, 18193036.
26. Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD, Brown PJ, Troussard X, Mossafa H, Enver T, et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008, 22:1440-1446. 10.1038/sj.leu.2405083, 18185523.
27. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, Lugar PL, Lagoo AS, Rizzieri DA, Friedman DR, et al. Patterns of microRNA expression characterize stages of human B cell differentiation. Blood 2009, 113:4586-4594. 10.1182/blood-2008-09-178186, 2680365, 19202128.
28. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010, 107:16228-16233. 10.1073/pnas.1009719107, 2941277, 20805506.
29. Lawrie CH, Cooper CD, Ballabio E, Chi J, Tramonti D, Hatton CS. Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy. Br J Haematol 2009, 145:545-548. 10.1111/j.1365-2141.2009.07642.x, 19298586.
30. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269. 10.1053/j.gastro.2008.04.003, 18555017.
31. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007, 12:457-466. 10.1016/j.ccr.2007.09.020, 17996649.
32. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009, 113:5237-5245. 10.1182/blood-2008-11-189407, 19144983.
33. Lawrie CH, Ballabio E, Dyar OJ, Jones M, Ventura R, Chi J, Tramonti D, Gooding S, Boultwood J, Wainscoat JS, et al. MicroRNA expression in chronic lymphocytic leukaemia. Br J Haematol 2009, 147:398-402. 10.1111/j.1365-2141.2009.07857.x, 19681887.
34. Felli N, Pedini F, Romania P, Biffoni M, Morsilli O, Castelli G, Santoro S, Chicarella S, Sorrentino A, Peschle C, Marziali G. MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica 2009, 94:479-486. 10.3324/haematol.2008.002345, 2663611, 19278969.
35. Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, Levy R. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007, 109:1636-1642. 10.1182/blood-2006-08-039024, 1794056, 17038524.
36. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007, 98:1914-1920. 10.1111/j.1349-7006.2007.00618.x, 17892514.
37. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417. 10.1182/blood-2008-12-194241, 2689042, 19179464.
38. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033. 10.1158/0008-5472.CAN-05-0137, 16024602.
39. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2006, 26:2799-2803.
40. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001, 15:981-986. 10.1038/sj.leu.2402125, 11417487.
41. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833. 10.1038/nature03552, 15944707.
42. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000, 95:1925-1930.
43. Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol 2007, 137:503-512. 10.1111/j.1365-2141.2007.06611.x, 17539773.
44. Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, Kolle G, Gabrielli B, Grimmond SM. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 2008, 9:R127. 10.1186/gb-2008-9-8-r127, 2575517, 18700987.
45. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 2008, 105:19678-19683. 10.1073/pnas.0811166106, 2598727, 19066217.
46. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006, 26:8191-8201. 10.1128/MCB.00242-06, 1636750, 16940181.
47. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer 2010, 126:1029-1035.
48. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252. 10.1038/sj.leu.2403784, 15902294.
49. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010, 101:241-249. 10.1111/j.1349-7006.2009.01385.x, 19891660.
50. Wei JJ, Wu X, Peng Y, Shi G, Olca B, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al. Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion. Clin Cancer Res 2010,
51. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003, 4:379-398. 10.1038/sj.thj.6200312, 14671610.
52. Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL, Proffitt J, Minvielle S, Avet-Loiseau H. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005, 19:275-278. 10.1038/sj.leu.2403586, 15538401.
53. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003, 31:265-273. 10.1016/S1046-2023(03)00155-5, 14597310.